Analysis of the performance of British pharmaceutical giant GSK in China

Pharmaceuticals, January 24 ( ) At the end of 2016, GlaxoSmithKline China announced a leadership change in its prescription drug business in Asia Pacific and ChinaThe promotion of the two Chinese leaders means GSK's ambitions and expectations for China's vast marketGSK has been challenged in China over the past few years, and in 2015 some of its products began to slash prices, becoming the first foreign drug company to slash prices in ChinaWhat will GSK's performance in China be like in 2017?GSK is one of the world's largest research and development-based multinational pharmaceuticalcompanies, products in the field of anti-virus, central nervous, respiratory treatment, GSK China business is mainly focused on prescription drugs, vaccines and other fieldsAfter three years of adjustment, GSK's performance in China is still poor, showing a downward trendthe overall market performance of GlaxoSmithKline in China in2015, according to CmH, GSK sales at the five terminals in 2015 was 11.33 billion yuan, the domesticpharmaceuticalmarket with 0.82% market share in the 23rd, in the domestic multinational pharmaceutical enterprises ranked 9thGSK's performance in China has been on a downward trend since the 2013 crisis, with a new global operating model introduced in 2015 that completely separates sales staff bonuses from salesIn order to win its market share in China, GSK took a price reduction approach, in 2015 GSK's three hepatitis B antiviral drugs Heptin, Hevelly and Verid through negotiations with local provinces and cities to reduce the average price by 20%-30%, becoming the first foreign drug companies in China to significantly reduce prices2013-2016E
GSK
product sales channel analysis in China
, The proportion of GSK products in the city grade showed a small declineWith the grass-roots first diagnosis, graded diagnosis and treatment and other grass-roots medical reform policy continues to advance in depth, prescription into the grass-rootshospitaland retailpharmacies, the county hospital terminal market potential is strong, the major foreign enterprises have sunk channels, is expected to 2016 GSK in the county grade hospital scale will increaseGSK products in China in 2015 are mainly concentrated in the field of systemic anti-infective drugs, respiratory drugs, nervous system drugs and other fieldsThe company's annual sales in China are the whole body anti-infective drug ramifdine, Adeforeester, cephalosporine sodium;GSKin China's end-of-product stakes in the company's share of the analysis
in 2015 GSK terminal sales of the top 10 products in the growth, 5 in a downward trend, the top 10 products accounted for 79% of the company's annual end sales, compared to 2014 only a decrease of 0.6%The following is an analysis of the key varietiesHepdin (Lamifdin) ramifdin nucleoside analogue, as an antiviral drug, used in the treatment of hepatobiliary disease caused by hepatitis B virus infection In 2015, ramifed tablets ranked second in the top10 brand of liver disease drug use in China, with annual sales of more than 2 billion yuan The product was originally GSK's main source of income in China, as a first-line drug for hepatitis B, but with the inflow of more products, anti-viral market competition is fierce, Hepedin's market share declined, by Boluding (Baishi MeiShibao) to catch up Adelfort (Hervei) Adforvirest is used to treat adult chronic hepatitis B patients who have been used to treat hepatitis B virus activity with a continuous rise in serum amino acid metastases (ALT or AST) or liver dysfunction altruism of liver histology activity, and should not be used in children and adolescents In 2015, the domestic Adelfowe ester market size reached 4 billion yuan, in the past three years GSK ranked second among 18 manufacturers, Zhengda Tianqing in the last three years occupied the first in the Adelfove ester market, but its market share is also in a downward trend Shamitoritikason (Shulidi) , the market size of the domestic Shamitoritika, 2015 reached 1.5 billion yuan, down 15.46 percent from 2014, the domestic anti-asthma drug TOP10 brand ranked fourth, but the only top 10 in the decline of the varieties In the field of respiratory drugs, GSK did not release the news of the price cut, the global sales of Shulidiet reported poor, but the recent sale of two anti-AIDS drugs Tivicay and Tirumeq helped the company offset the adverse effects of Scioli paroxetine Paroxetine is a benzodiazepine derivative that selectively inhibits 5-HT transport, blocks the re-intake of 5-HT from the synaptic pre-synapses membrane, prolongs and increases the effect seamounting 5-HT, resulting in antidepressant effects Zhongkang CMH data data In 2015, GSK's hydrochloric acid paroxetine tablets accounted for 1.09% of the psychotropic drug market, with annual sales of more than 600 million yuan, and the variety has also been on a downward trend in the past three years Dotlavina GSK's VV Healthcare anti-AI new drug Tivicay was officially launched in China in mid-2016 On December 30, 2015, Tweedkai obtained approval for a new drug from China's State Food and Drug Administration to treat adults infected with human immunodeficiency virus (HIV) and children over 12 years of age through a combination of other antiretroviral drugs Tweede can inhibit the enzymes needed for HIV replication (i.e integration enzymes) and block further replication of the virus by binding the enzyme to act on the site For the first time, the World Health Organization's HIV anti-virus guidelines, updated in 2015, also include Tweedas as the only integrated enzyme inhibitor sits in the first-line options for first-time treatment of patients GSK Ji Haiwei said it would continue to work with relevant chinese government departments to include the anti-AIDS drug Tweede in the national list of free treatment to improve the accessibility of drugs for patients GSK accounted for a relatively large number of key products in 2015 are generally in a downward trend, its head of government affairs in China Zhang Yingwei said that GSK's slow growth rate contains opportunities GSK, which sold its oncology business to Novartis, focused on respiratory, antiviral and vaccine businesses, and Mr Zhang said the launch of the HPV vaccine in China and the expansion of the anti-AIDS drug Tweedkai would have a positive impact on weak performance in The region Can GSK's performance in China pick up in 2017? See